Citations

Showing 10 of 108162 citations.

Comparative connectivity correlates of dystonic and essential tremor deep brain stimulation
Tsuboi, Takashi , Wong, Joshua K. , Burns, Mathew R, Ramirez‐Zamora, Adolfo , Shukla, Aparna Wagle, Foote, Kelly D. , Okun, Michael S. , Middlebrooks, Erik H. , Okromelidze, Lela , Okun, Michael S , Middlebrooks, Erik H , Wong, Joshua K , Tsuboi, Takashi , Ramirez-Zamora, Adolfo , Eisinger, Robert Stephen , Almeida, Leonardo , Shukla, Aparna Wagle , Grewal, Sanjeet S.

Mayo Clinic

Brain | February 26, 2021 | Volume: 144 | Issue: 6 | Pages: 1774-1786

10.1093/brain/awab074 | PMID 33889943 Get It

AbstractThe pathophysiology of dystonic tremor and essential tremor remains partially understood. In patients with medication-refractory dystonic tremor or essential tremor, deep brain stimulation (DBS) targeting the thalamus or posterior subthalamic area has evolved into a promising treatment option. However, the optimal DBS targets for these disorders remains unknown. This retrospective study explored the optimal targets for DBS in essential tremor and dystonic tremor using a combination of volumes of tissue activated estimation and functional and structural connectivity analyses. We included 20 patients with dystonic tremor who underwent unilateral thalamic DBS, along with a matched cohort of 20 patients with essential tremor DBS. Tremor severity was assessed preoperatively and approximately 6 months after DBS implantation using the Fahn-Tolosa-Marin Tremor Rating Scale. The tremor-suppressing effects of DBS were estimated using the percentage improvement in the unilateral tremor-rating scale score contralateral to the side of implantation. The optimal stimulation region, based on the cluster centre of gravity for peak contralateral motor score improvement, for essential tremor was located in the ventral intermediate nucleus region and for dystonic tremor in the ventralis oralis posterior nucleus region along the ventral intermediate nucleus/ventralis oralis posterior nucleus border (4 mm anterior and 3 mm superior to that for essential tremor). Both disorders showed similar functional connectivity patterns: a positive correlation between tremor improvement and involvement of the primary sensorimotor, secondary motor and associative prefrontal regions. Tremor improvement, however, was tightly correlated with the primary sensorimotor regions in essential tremor, whereas in dystonic tremor, the correlation was tighter with the premotor and prefrontal regions. The dentato-rubro-thalamic tract, comprising the decussating and non-decussating fibres, significantly correlated with tremor improvement in both dystonic and essential tremor. In contrast, the pallidothalamic tracts, which primarily project to the ventralis oralis posterior nucleus region, significantly correlated with tremor improvement only in dystonic tremor. Our findings support the hypothesis that the pathophysiology underpinning dystonic tremor involves both the cerebello-thalamo-cortical network and the basal ganglia-thalamo-cortical network. Further our data suggest that the pathophysiology of essential tremor is primarily attributable to the abnormalities within the cerebello-thalamo-cortical network. We conclude that the ventral intermediate nucleus/ventralis oralis posterior nucleus border and ventral intermediate nucleus region may be a reasonable DBS target for patients with medication-refractory dystonic tremor and essential tremor, respectively. Uncovering the pathophysiology of these disorders may in the future aid in further improving DBS outcomes.
The Time Is Now to Understand and Address Sex-Related Disparities in Gastroenterology and Hepatology
Shaukat, Aasma , Oxentenko, Amy S.

Mayo Clinic

American Journal of Gastroenterology | February 26, 2021 | Volume: 116 | Issue: 3 | Pages: 441-443

10.14309/ajg.0000000000001185 | PMID 33657032 Get It

Abstract Many gastrointestinal disorders, autoimmune diseases, and pregnancy-related conditions preferentially impact women. This issue of The American Journal of Gastroenterology focuses on women's health in the context of gastrointestinal and liver disease. This editorial highlights the current issue's contents and seeks to spark the conversations to bring awareness to the many issues faced by women as both patients and practitioners.
Screening Women for Anal Cancers: Guidance for Health Care Professionals
Vegunta, Suneela , Whited, M. Helen, Long, Margaret E. , Shah, Amit A, Shah, Amit

Mayo Clinic

American Journal of Gastroenterology | February 26, 2021 | Volume: 116 | Issue: 3 | Pages: 509-516

10.14309/ajg.0000000000001186 | PMID 33606380 Get It

Anal cancer is rare in the general population but is steadily increasing in incidence over the past decade especially in women . Identification and screening of women with high risk facilitates detection of anal precancer and early-stage cancer, improves survival, and potentially uses less invasive therapies compared with the conventional chemoradiation treatments used for advanced cancers. No recently published guidelines currently describe details about screening women for anal squamous cell cancer (ASCC). The available evidence supports the existence of groups of women with higher prevalence of ASCC (e.g., women with human immunodeficiency virus, immune suppression, or previous lower-genital high-grade lesion or cancer) who would likely benefit from screening with some combination of anal cytology and human papillomavirus testing. Additional research is needed to establish the cost-effectiveness and the influence of screening on ASCC mortality rates.
Mortality Within 30 Days After Head and Neck Free Flap Reconstruction: A Systematic Review
Chicco, Maria , Huang, Tony Chieh‐Ting , Cheng, Hsu-Tang

Mayo Clinic

Journal of Craniofacial Surgery | February 26, 2021 | Volume: 32 | Issue: 5 | Pages: 1738-1741

10.1097/scs.0000000000007548 | PMID 34081420 Get It

Objective: The aim of this systematic review is to analyze the 30-day postoperative mortality in patients undergoing free flap reconstruction for head and neck cancer published in literature and to identify associated factors. Methods: The authors performed a literature search between January 1950 and February 2020 in PubMed, EMBASE, and Scopus, using a combination of Medical Subject Headings headings and text keywords related to head and neck cancer; microsurgery or free flap reconstruction; and 30-day mortality. Inclusion criteria were: original studies in English reporting on 30-day mortality after head and neck free flap reconstruction in adult population. Results: Thirty-one publications reported on a total of 13,447 patients who underwent head and neck free flap reconstruction. The published 30-day postoperative mortality ranged from 0% to 6.3%, with an average of 1.21%. A number of studies examined the association between mortality and body mass index, American Society of Anesthesiologists, and comorbidity score and age. One study found that underweight patients had significantly higher mortality. Two studies found no association between the American Society of Anesthesiologists score and 30-day postoperative mortality; however, 1 study reported significantly higher mortality with increased comorbidity score. Regarding association with age, 3 studies found significant higher mortality in older patients, while 5 studies found no difference. Conclusions: The average 30-day postoperative mortality in patients undergoing head and neck free flap reconstruction is 1.21% and is; therefore, not negligible. Careful patient selection and preoperative optimization are essential in order to reduce mortality in head neck free flap reconstruction.
Diffuse Gliomas of the Brainstem and Cerebellum in Adults Show Molecular Heterogeneity
Eschbacher, Kathryn L. , Alvi, Mohammed Ali , Jenkins, Sarah M. , Ruff, Michael W. , Kerezoudis, Panagiotis , Neth, Bryan J. , Pasion, Romela, Kizilbash, Sani H. , Neth, Byran J. , Kizilbash, Sani H , Alvi, Mohammed Ali , Ida, Cristiane M. , Johnson, Derek R. , Daniels, David J. , Raghunathan, Aditya

Mayo Clinic

American Journal of Surgical Pathology | February 26, 2021 | Volume: 45 | Issue: 8 | Pages: 1082-1090

10.1097/pas.0000000000001690 | PMID 33606385 Get It

Posterior fossa (PF) diffuse gliomas in pediatric patients frequently harbor the H3 K27M mutation. Among adults, PF diffuse gliomas are rare, with limited data regarding molecular features and clinical outcomes. We identified 28 adult PF diffuse glioma patients (17 males; median: 50 y, range: 19 to 78 y), with surgery performed at our institution (13 brainstem; 15 cerebellum). Histologic subtypes included anaplastic astrocytoma (n=21), glioblastoma (n=6), and diffuse astrocytoma (n=1). Immunohistochemistry was performed for H3 K27M (n=26), IDH1-R132H (n=28), and ATRX (n=28). A 150-gene neuro-oncology-targeted next-generation sequencing panel was attempted in 24/28, with sufficient informative material in 15 (51.7%). Tumors comprised 4 distinct groups: driver mutations in H3F3A (brainstem=4; cerebellum=2), IDH1 (brainstem=4; cerebellum=4), TERT promotor mutation (brainstem=0; cerebellum=3), and none of these (n=5), with the latter harboring mutations of TP53 , PDGFRA , ATRX , NF1 , and RB1 . All TERT promoter–mutant cases were IDH-wild-type and arose within the cerebellum. To date, 20 patients have died of disease, with a median survival of 16.3 months, 1-year survival of 67.5%. Median survival within the subgroups included: H3F3A =16.4 months, IDH mutant=113.4 months, and TERT promoter mutant=12.9 months. These findings suggest that PF diffuse gliomas affecting adults show molecular heterogeneity, which may be associated with patient outcomes and possible response to therapy, and supports the utility of molecular testing in these tumors.
Uveal melanoma: laboratory advances and new frontiers in patient care
Xu, Timothy T. , Moser, Justin C. , Dalvin, Lauren A.

Mayo Clinic

Current Opinion in Ophthalmology | February 26, 2021 | Volume: 32 | Issue: 3 | Pages: 301-308

10.1097/icu.0000000000000744 | PMID 33606406 Get It

Purpose of review To review recent advancements in the genetic understanding, diagnosis, prognosis, and treatment of uveal melanoma (UM). Recent findings UM is a molecularly distinct melanocytic malignancy driven by mutations in GNAQ or GNA11, with mitogen-activated protein kinase pathway upregulation. Earlier diagnosis and treatment are important factors for improving life prognosis. These goals can be aided by more objective multimodal imaging risk factors for the prediction of malignant nevus transformation and novel treatment strategies such as customized radiation fields and nanoparticle therapy to reduce vision-threatening treatment side effects. The risk for metastatic disease can be reliably predicted through gene expression profiling or the Cancer Genome Atlas project classification, and combined use of clinical tumor features with molecular data allows for highly individualized patient prognosis. Patients with high-risk UM should be considered for clinical trials of adjuvant therapy to prevent metastatic disease. For patients with clinically evident metastasis, combination immunotherapy regimens, T cell-based therapies, and focal adhesion kinase inhibitors offer hope for improved clinical response rates. Summary Improved understanding of UM molecular pathogenesis and clinical trials of targeted therapy for prevention and treatment of metastatic disease may improve patient survival for this challenging disease.
Scoping review of COVID-19-related systematic reviews and meta-analyses: can we really have confidence in their results?
Wurth, Rachel , Hajdenberg, Michelle , Copacino, Caroline E., Gharib, Omar A M , Porter, Forbes D. , Hiremath, Swapnil , Eisenhofer, Graeme , Bornstein, Stefan R. , Brito, Juan P. , González‐González, José Gerardo , Rodríguez‐Gutiérrez, René , Hannah‐Shmouni, Fady , Barrera, Francisco J. , Moreno-Peña, Pablo J, González-González, José Gerardo , Rodríguez-Gutiérrez, René , Hannah-Shmouni, Fady , Brito, Juan P , Shekhar, Skand , Moreno‐Peña, Pablo J. , Hall, Janet Elizabeth , Schiffrin, Ernesto L. , Stratakis, Constantine A.

Mayo Clinic

Postgraduate Medical Journal | February 26, 2021 | Volume: 98 | Issue: 1159 | Pages: 372-379

10.1136/postgradmedj-2020-139392 | PMID 33637639 Get It

AbstractAimThe aim of this study was to systematically appraise the quality of a sample of COVID-19-related systematic reviews (SRs) and discuss internal validity threats affecting the COVID-19 body of evidence.DesignWe conducted a scoping review of the literature. SRs with or without meta-analysis (MA) that evaluated clinical data, outcomes or treatments for patients with COVID-19 were included.Main outcome measuresWe extracted quality characteristics guided by A Measurement Tool to Assess Systematic Reviews-2 to calculate a qualitative score. Complementary evaluation of the most prominent published limitations affecting the COVID-19 body of evidence was performed.ResultsA total of 63 SRs were included. The majority were judged as a critically low methodological quality. Most of the studies were not guided by a pre-established protocol (39, 62%). More than half (39, 62%) failed to address risk of bias when interpreting their results. A comprehensive literature search strategy was reported in most SRs (54, 86%). Appropriate use of statistical methods was evident in nearly all SRs with MAs (39, 95%). Only 16 (33%) studies recognised heterogeneity in the definition of severe COVID-19 as a limitation of the study, and 15 (24%) recognised repeated patient populations as a limitation.ConclusionThe methodological and reporting quality of current COVID-19 SR is far from optimal. In addition, most of the current SRs fail to address relevant threats to their internal validity, including repeated patients and heterogeneity in the definition of severe COVID-19. Adherence to proper study design and peer-review practices must remain to mitigate current limitations.
Quantitative magnetic resonance imaging for chronic liver disease
Cunha, Guilherme Moura , Navin, Patrick J. , Venkatesh, Sudhakar K. , Moura Cunha, Guilherme , Venkatesh, Sudhakar K , Navin, Patrick , Fowler, Kathryn J. , Ehman, Richard L. , Sirlin, Claude B.

Mayo Clinic

The British Journal of Radiology | February 26, 2021 | Volume: 94 | Issue: 1121 | Pages: No page available

10.1259/bjr.20201377 | PMID 33635729 Get It

Chronic liver disease (CLD) has rapidly increased in prevalence over the past two decades, resulting in significant morbidity and mortality worldwide. Historically, the clinical gold standard for diagnosis, assessment of severity, and longitudinal monitoring of CLD has been liver biopsy with histological analysis, but this approach has limitations that may make it suboptimal for clinical and research settings. Magnetic resonance (MR)-based biomarkers can overcome the limitations by allowing accurate, precise, and quantitative assessment of key components of CLD without the risk of invasive procedures. This review briefly describes the limitations associated with liver biopsy and the need for non-invasive biomarkers. It then discusses the current state-of-the-art for MRI-based biomarkers of liver iron, fat, and fibrosis, and inflammation.
Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma
Diefenbach, Catherine , Peters, Brandilyn A. , Li, Huilin , Raphael, Bruce G. , Moskovits, Tibor, Hymes, Kenneth B., Schlüter, Jonas , Chen, J., Bennani, N. Nora , Witzig, Thomas E. , Chen, John J. , Witzig, T.E. , Bennani, N Nora , Chen, John J , Diefenbach, Catherine S , Ahn, Jiyoung

Mayo Clinic

Blood Advances | February 26, 2021 | Volume: 5 | Issue: 5 | Pages: 1194-1198

10.1182/bloodadvances.2020003129 | PMID 33635332 Get It

Abstract B-cell non-Hodgkin lymphoma cell survival depends on poorly understood immune evasion mechanisms. In melanoma, the composition of the gut microbiota (GMB) is associated with immune system regulation and response to immunotherapy. We investigated the association of GMB composition and diversity with lymphoma biology and treatment outcome. Patients with diffuse large B-cell lymphoma (DLBCL), marginal zone (MZL), and follicular lymphoma (FL) were recruited at Mayo Clinic, Minnesota, and Perlmutter Cancer Center, NYU Langone Health. The pretreatment GMB was analyzed using 16S ribosomal RNA gene sequencing. We examined GMB compositions in 3 contexts: lymphoma patients (51) compared with healthy controls (58), aggressive (DLBCL) (8) compared with indolent (FL, MZL) (18), and the association of GMB with immunochemotherapy treatment outcomes (8 responders, 6 nonresponders). Respectively, we found that the pretreatment GMB in lymphoma patients had a distinct composition compared with healthy controls (P < .001); GMB compositions in DLBCL patients were significantly different than indolent patients (P = .01) with a trend toward reduced microbial diversity in DLBCL patients (P = .08); and pretreatment GMB diversity and composition were significant predictors of treatment responses (P = .01). The impact of these pilot results is limited by our small sample size, and should be considered a proof of principle. If validated, our results could lead toward improved treatment outcomes by improving medication stewardship and informing which GMB-targeted therapies should be tested to improve patient outcomes.
PRODIGY Score and Post-hoc Analysis of Previous Studies of Postoperative Respiratory Depression
Morales, Diana J. Valencia , Valencia Morales, Diana, Valencia Morales, Diana J , Šprung, Juraj , Weingarten, Toby N.

Mayo Clinic

Anesthesia & Analgesia | February 26, 2021 | Volume: 132 | Issue: 3 | Pages: e44-e45

10.1213/ane.0000000000005339 | PMID 33591102 Get It